Posts by Jim Miller

Jim Miller is the founder and president of PharmSource Information Services, Inc. A preeminent expert in bio/pharmaceutical outsourcing, Jim established and presides over the industry’s principal resource for serious consumers of information on contract drug development and manufacturing, PharmSource STRATEGIC ADVANTAGE. He is editor and publisher of Bio/Pharmaceutical Outsourcing Report and Emerging Markets Outsourcing Report.

Moving Biopharma Manufacturing Back to the US Will Take Years – Here’s Why

US president Donald Trump’s insistence that manufacturing will move back to the US has sparked a wave of promises from big biopharma firms over the sector’s future. Leaving aside the fact that biopharmaceutical manufacturing never really left the US, the realities of the current manufacturing environment means moving will take time. Here’s why: Manufacturing capacity […]

Learn more

The Tide Stays High

Robust venture capital investment gives CDMOs and CROs a positive outlook for 2017. A year ago, the outlook for contract services was a little uncertain. Equity markets’ appetite for public offerings from emerging bio/pharmaceutical companies had significantly diminished: valuations of emerging bio/pharma companies, as measured by the NASDAQ Biotechnology Index (NBI), had declined by 15% […]

Learn more

Catalent to Acquire Accucaps

Catalent has agreed to acquire softgel manufacturer Accucaps Industries Ltd. Financial details of the transaction were not disclosed, but analysts that follow Catalent put the price at $75 million, representing a multiple of 10x EBITDA. The deal is subject to Canadian regulatory approval. Accucaps is owned by Canadian generic pharmaceutical company Apotex, a detail not […]

Learn more

Growing Turkish Pharma Market Attracts Investment Despite Challenges

A growing pharmaceutical market, solid infrastructure and ready access to other emerging markets, such as North Africa and the Middle East, as well as Eastern Europe, make Turkey an attractive location for global pharmaceutical companies. But an emphasis on localization, tough pricing regulations, a depreciating currency and a sluggish drug approval system make the market […]

Learn more

Five Themes That Will Drive the CMO Industry

CMO executives are focusing on M&A activity, new business models, and fundraising limits. Trade shows provide a good opportunity to gauge the temperature of the contract development and manufacturing organization (CDMO) industry and find out which trends and concerns are most on people’s minds. Five themes really stood out from conversations at the CPhI Worldwide […]

Learn more

Trial Registrations Reflect Improved Funding

The impact of the strong funding environment for emerging bio/pharma companies is being reflected in new clinical trial starts. An analysis of new clinical trial registrations in the clinicaltrials.gov database indicates that Phase I and II trial starts for which an emerging bio/pharma company is the sponsor or principal collaborator were up 65% in the […]

Learn more

Peptide API Market Growth Expected to Continue

CMOs with existing expertise in and capacity for development and manufacture of peptide drugs may find themselves uniquely positioned to take advantage of a surge in interest in such products. As the ability to synthesize these products grows and more dosage forms become available, more companies are adding peptide products—including potential biosimilars as some of […]

Learn more

Innovation vs. Capacity: How CMOs Compete

The strategies of a innovation-driven CMO may be different than a capacity-driven CMO. While industry participants and observers talk about the “CMO industry,” they know that it is not an undifferentiated mass of manufacturers. The contract manufacturing organization (CMO) industry can be segmented along obvious lines such as API versus drug product manufacturers, biologics versus […]

Learn more

What’s Next for the CMO Industry?

CMOs that offer an innovative service-oriented model will dominate the industry. Contract manufacturing and contract development and manufacturing organizations (CMOs and CDMOs) are an entrenched and critical component of the bio/pharmaceutical industry, but they have proven to be more important to some segments of the industry than others. A bio/pharma company’s relationship with its CMOs […]

Learn more